Adage Capital Partners Gp, L.L.C. Nuvalent, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51.6 Billion
- Q1 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Nuvalent, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 397,000 shares of NUVL stock, worth $30 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
397,000
Previous 680,000
41.62%
Holding current value
$30 Million
Previous $53.2 Million
47.11%
% of portfolio
0.05%
Previous 0.1%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
216Shares Held
60.9MCall Options Held
319KPut Options Held
211K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.36 Billion32.3% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$398 Million19.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.44MShares$335 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$228 Million0.01% of portfolio
-
Commodore Capital LP New York, NY1.86MShares$140 Million12.88% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.25B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...